Compositions and Methods for Regulating CAR T Cells

• US 20150140019A1
• Filed: 07/12/2013
• Published: 05/21/2015
• Est. Priority Date: 07/13/2012
• Status: Abandoned Application

• Current Assignee: Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Original Assignee: Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Inventors: June, Carl H., Levine, Bruce L., Kalos, Michael D.
• Application Number:
  US14/408,851
• Publication Number:
  US 20150140019A1
• Time in Patent Office: Days
• US Class Current: 424/178.1
• CPC Class Codes: A61K 47/6803 Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
• CPC Class Codes: A61K 47/6849 the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2809 against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 2317/77 Internalization into the cell

Abstract

The present invention provides compositions and methods for inhibiting the depletion of healthy tissue during CAR T cell therapy. In another embodiment, the invention includes a drug-molecule conjugate which is administered to a subject receiving CAR T cell therapy, where the conjugate binds to the CAR resulting in internalization of the conjugate and inhibition of T cell activity and/or death of the T cell.

Claims

1. A drug-molecule conjugate comprising a drug and a molecule which binds to a CAR expressed on the surface of a cell.

2. The conjugate of claim 1, wherein binding of the conjugate to the CAR results in internalization of the conjugate into the cell.

3. The conjugate of claim 1, wherein binding of the conjugate to the CAR results in the drug-mediated death of the cell.

4. The conjugate of claim 1, wherein the cell is a T cell and wherein binding of the conjugate to the CAR results in the drug-mediated inhibition of the activation of the T cell.

5. The conjugate of claim 1, wherein the molecule is selected from the group consisting of an antibody, a protein, a peptide, a nucleotide, a small molecule, and fragments thereof.

6. A method for inhibiting the depletion of healthy tissue during CAR T cell therapy comprising administering a drug-molecule conjugate comprising a drug and a molecule to a subject receiving CAR T cell therapy, wherein the molecule binds to a CAR expressed on the surface of a T cell.

7. The method of claim 6, wherein binding of the conjugate to the CAR results in internalization of the conjugate into the cell.

8. The method of claim 6, wherein the binding of the conjugate to the CAR results in the drug-mediated death of the cell.

9. The method of claim 6, wherein the binding of the conjugate to the CAR results in the drug-mediated inhibition of the activation of the T cell.

10. The method of claim 6, wherein the molecule is selected from the group consisting of an antibody, a protein, a peptide, a nucleotide, a small molecule, and fragments thereof.